Assessing the Risk of Birth Defects Associated with Exposure to Fixed-Dose Combined Antituberculous Agents during Pregnancy in Rats

Table 2

Incidence of growth retardation and size abnormality in fetuses of treated rats.

Groups	SE	BW + PW (g) (Mean ± SEM)	BW (g) (Mean ± SEM)	PW (g) (Mean ± SEM)	CRL (cm) (Mean ± SEM)	UCL (cm) (Mean ± SEM)	TL (CM) (Mean ± SEM)
Group 1	OR	4.793±0.6750	4.173±0.6165	0.6205±0.01799	4.583±0.1222	2.967±0.1453	1.267±0.04216
Group 2	OR	4.181±0.1340^∗	3.567±0.06215^∗	0.4818±0.01337^∗	4.733±0.09189	2.883±0.1621	1.200±0.05164
Group 3	OR	3.638±0.233^∗	3.075±0.1341^∗	0.6233±0.03565^∗	4.183±0.2469	2.800±0.1317	1.117±0.05426

SE: stage of exposure, OR: organogenesis, BW + PW: body weight + placenta weight, BW: body weight, PW: placenta weight, CRL: crown-rump length, UCL: umbilical cord length, TL: tail length.
^∗𝑃≤0.05 compared with group 1 (control).
Group 1: control group. Group 2: administered with clinical dose (51.4 mg/kg/day) of fixed-dose combined antituberculous agents. Group 3: administered with clinical dose of fixed-dose combined antituberculous agents plus 10 mg/kg/day of Vitamin C.